vilanterol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
bronchodilators, phenethylamine derivatives 4799 503068-34-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • GW642444X
  • vilanterol
  • Breo Ellipta
  • vilanterol trifenatate
  • GW642444M
Vilanterol is a long-acting beta2-adrenergic agonist. The clinical relevance of this in vitro finding is unknown. Although beta2-receptors are the predominant adrenergic receptors in bronchial smooth muscle and beta1-receptors are the predominant receptors in the heart, there are also beta2-receptors in the human heart comprising 10% to 50% of the total beta-adrenergic receptors. The precise function of these receptors has not been established, but they raise the possibility that even highly selective beta2-agonists may have cardiac effects. The pharmacologic effects of beta2-adrenergic agonist drugs, including vilanterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.
  • Molecular weight: 486.43
  • Formula: C24H33Cl2NO5
  • CLOGP: 3.19
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 4
  • TPSA: 91.18
  • ALOGS: -5.61
  • ROTB: 16
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 2.38 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 25.70 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.06 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.40 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.581 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 41.210 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 1.528 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 9.528 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 3.920 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 17.750 % High 1
herg hERG pIC50 5.320 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 7.551 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 156.315 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 9 % High 1
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IGF1R,IKBKB,ITK,JAK1,JAK2,JAK3,KIT,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 63
kinase-selectivity-class ACVRL1,AXL,BRAF,CDK4,CDK9,DDR1,EIF2AK3,EPHB4,GRK2,MAP2K6,MAPK7,PDK4,PIK3CD,SIK2,SIK3,STK33,TEK 17
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 24.266 Moderate 0.66
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 23.281 High 1
mh-clint Mouse hepatocyte intrinsic clearance 107.647 High 1
mppb Mouse plasma protein binding (% unbound) 7.860 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 26.853 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 Moderate 0.66
pppb Pig plasma protein binding (% unbound) 10.540 % High 1
rat-kpuu-brain Rat brain Kpuu 0.028 % Moderate 0.66
rh-clint Rat hepatocyte intrinsic clearance 156.315 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 37.380 % High 1
rppb Rat plasma protein binding (% unbound) 11.140 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 763.836 uM High 1

Approvals:

DateAgencyCompanyOrphan
May 10, 2013 FDA GLAXO GRP LTD
Nov. 13, 2013 EMA GlaxoSmithKline (Ireland) Limited

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Analgesic therapy 87.69 44.66 15 2146 657 90625629
Antacid therapy 85.97 44.66 15 2146 739 90625547
Appendicolith 85.83 44.66 15 2146 746 90625540
Drug therapy 84.91 44.66 15 2146 794 90625492
Anticoagulant therapy 84.77 44.66 15 2146 802 90625484
Lactose intolerance 79.57 44.66 18 2143 3351 90622935
Blood creatinine increased 77.83 44.66 41 2120 101345 90524941
Hydronephrosis 64.67 44.66 20 2141 12382 90613904
Obstructive airways disorder 64.61 44.66 24 2137 25845 90600441
Hyperphosphataemia 62.13 44.66 15 2146 3696 90622590
Blood phosphorus increased 59.88 44.66 15 2146 4303 90621983
Diabetes mellitus 54.80 44.66 28 2133 64847 90561439
Aortic stenosis 54.17 44.66 15 2146 6321 90619965
Secondary hypogonadism 52.22 44.66 8 2153 173 90626113
Haemoptysis 51.96 44.66 22 2139 33298 90592988
Steroid diabetes 51.74 44.66 12 2149 2490 90623796
Blood uric acid increased 51.27 44.66 15 2146 7689 90618597
Activated partial thromboplastin time prolonged 51.04 44.66 15 2146 7810 90618476
Full blood count abnormal 49.98 44.66 22 2139 36575 90589711
End stage renal disease 49.69 44.66 15 2146 8556 90617730
Subclavian vein thrombosis 48.31 44.66 11 2150 2105 90624181
Appendicitis 47.08 44.66 15 2146 10216 90616070
Lacrimation increased 45.99 44.66 19 2142 27043 90599243

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 482.55 86.26 146 6255 13310 42601624
Appendicitis 429.09 86.26 148 6253 20465 42594469
Cardiogenic shock 336.95 86.26 144 6257 35496 42579438
Ventricular fibrillation 319.09 86.26 132 6269 29991 42584943
Blood phosphorus increased 316.01 86.26 104 6297 12421 42602513
Stress 294.84 86.26 140 6261 44072 42570862
Ascites 290.46 86.26 150 6251 56528 42558406
Abdominal distension 244.14 86.26 145 6256 71590 42543344
Blood uric acid increased 201.99 86.26 79 6322 15468 42599466
Multiple organ dysfunction syndrome 201.75 86.26 144 6257 96891 42518043
Myasthenia gravis 199.14 86.26 79 6322 16058 42598876
Hyponatraemia 193.71 86.26 143 6258 101319 42513615
Dry mouth 191.04 86.26 101 6300 39778 42575156
Blood cholesterol increased 169.84 86.26 82 6319 26659 42588275
Hyperphosphataemia 158.09 86.26 63 6338 12941 42601993
General physical health deterioration 149.56 86.26 146 6255 151100 42463834
Incorrect route of product administration 146.71 86.26 72 6329 24233 42590701
Iron deficiency 135.88 86.26 54 6347 11007 42603927
Constipation 135.50 86.26 143 6258 162148 42452786
Bacterial infection 126.06 86.26 68 6333 27811 42587123
Neuralgia 125.67 86.26 66 6335 25581 42589353
Hypophosphataemia 123.27 86.26 61 6340 20884 42594050
Abdominal pain 118.39 86.26 144 6257 190327 42424607
Sepsis 113.15 86.26 144 6257 199190 42415744
Sleep disorder 108.10 86.26 75 6326 48020 42566914
Sleep disorder therapy 107.32 86.26 40 6361 6854 42608080
Analgesic therapy 105.77 86.26 39 6362 6485 42608449
Thrombosis 103.09 86.26 84 6317 68427 42546507
Drug therapy 91.98 86.26 35 6366 6345 42608589

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Appendicolith 642.55 65.75 160 8206 14095 110566838
Appendicitis 541.63 65.75 162 8204 28302 110552631
Blood phosphorus increased 426.56 65.75 119 8247 16221 110564712
Cardiogenic shock 415.81 65.75 158 8208 57180 110523753
Ventricular fibrillation 385.12 65.75 137 8229 41176 110539757
Ascites 361.27 65.75 164 8202 92644 110488289
Blood uric acid increased 289.36 65.75 94 8272 21435 110559498
Stress 287.68 65.75 146 8220 105202 110475731
Abdominal distension 258.21 65.75 162 8204 174941 110405992
Myasthenia gravis 253.28 65.75 85 8281 21426 110559507
Hyperphosphataemia 246.69 65.75 78 8288 16303 110564630
Multiple organ dysfunction syndrome 245.60 65.75 149 8217 151561 110429372
Hyponatraemia 198.95 65.75 150 8216 217503 110363430
Analgesic therapy 194.31 65.75 54 8312 7230 110573703
Constipation 191.43 65.75 181 8185 357605 110223328
Iron deficiency 186.21 65.75 65 8301 18411 110562522
Bacterial infection 184.06 65.75 83 8283 45953 110534980
Sepsis 181.59 65.75 169 8197 327177 110253756
Drug therapy 176.05 65.75 50 8316 7241 110573692
Diabetes mellitus 164.22 65.75 99 8267 99282 110481651
Sleep disorder therapy 157.06 65.75 46 8320 7425 110573508
Hypophosphataemia 155.81 65.75 67 8299 33115 110547818
Abdominal pain 153.60 65.75 191 8175 512798 110068135
Neuralgia 146.31 65.75 72 8294 48406 110532527
Incorrect route of product administration 143.89 65.75 78 8288 63983 110516950
Dry mouth 136.05 65.75 116 8250 199832 110381101
Anticoagulant therapy 135.01 65.75 38 8328 5323 110575610
Antacid therapy 134.16 65.75 38 8328 5446 110575487
Thrombosis 134.01 65.75 90 8276 108572 110472361
Aortic stenosis 131.79 65.75 46 8320 13013 110567920
General physical health deterioration 129.81 65.75 160 8206 425135 110155798
Chronic obstructive pulmonary disease 126.49 65.75 87 8279 109071 110471862
Activated partial thromboplastin time prolonged 117.75 65.75 49 8317 22319 110558614
Obstructive airways disorder 114.33 65.75 60 8306 46089 110534844
End stage renal disease 106.21 65.75 45 8321 21428 110559505
Blood cholesterol increased 105.30 65.75 97 8269 184688 110396245
Gout 91.87 65.75 48 8318 36518 110544415
Intentional product misuse 82.01 65.75 73 8293 132831 110448102
Somnolence 81.20 65.75 106 8260 297343 110283590
Full blood count abnormal 80.22 65.75 51 8315 56001 110524932
Bacteroides infection 79.48 65.75 22 8344 2897 110578036
Hyperlipidaemia 78.64 65.75 43 8323 35805 110545128
Pulmonary embolism 75.63 65.75 87 8279 214387 110366546
Respiratory symptom 72.83 65.75 31 8335 14914 110566019
Sleep disorder 72.44 65.75 82 8284 198562 110382371
Total lung capacity decreased 71.54 65.75 25 8341 7089 110573844
Haemoptysis 71.32 65.75 52 8314 71302 110509631
Blood calcium increased 70.37 65.75 32 8334 18008 110562925

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R03AK10 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
ATC R03AL03 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC R03AL08 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA MoA N0000009922 Adrenergic beta2-Agonists
FDA EPC N0000175779 beta2-Adrenergic Agonist
CHEBI has role CHEBI:35522 β-adrenergic agonist
CHEBI has role CHEBI:35523 bronchodilator agent
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:49167 anti-asthmatic drug
CHEBI has role CHEBI:50857 anti-allergic agent

Related Drugs by ATC class:

R03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics 13 drugs
beclometasone dipropionatebudesonidecromoglicic acidepinephrinefluticasone furoatefluticasone propionateformoterolindacaterolisoprenalinemometasone furoatereproterolsalbutamol show all 13 →
R03AL Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids 14 drugs
aclidinium bromidebeclometasone dipropionatebudesonidefenoterolfluticasone furoateformoterolglycopyrronium bromideindacaterolipratropiummometasone furoateolodaterolsalbutamol show all 14 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic obstructive lung disease indication 13645005 DOID:3083
Chronic bronchitis indication 63480004 DOID:6132
Pulmonary emphysema indication 87433001
Asthma indication 195967001 DOID:2841




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.07 acidic
pKa2 9.28 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH ANORO ELLIPTA GLAXOSMITHKLINE N203975 Dec. 18, 2013 RX POWDER INHALATION 8511304 June 14, 2027 INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.
0.05MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 12, 2023 RX POWDER INHALATION 8511304 June 14, 2027 MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 5 YEARS AND OLDER. RECOMMENDED DOSAGES: BREO 100/25 OR 200/25 AGES 18 YEARS AND OLDER; BREO 100/25 AGES 12-17 YEARS, AND BREO 50/25, AGES 5-11 YEARS
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION 8511304 June 14, 2027 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION 8511304 June 14, 2027 LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION 8511304 June 14, 2027 MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 5 YEARS AND OLDER. RECOMMENDED DOSAGES: BREO 100/25 OR 200/25 AGES 18 YEARS AND OLDER; BREO 100/25 AGES 12-17 YEARS, AND BREO 50/25, AGES 5-11 YEARS
0.2MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 April 30, 2015 RX POWDER INHALATION 8511304 June 14, 2027 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.2MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 April 30, 2015 RX POWDER INHALATION 8511304 June 14, 2027 MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 5 YEARS AND OLDER. RECOMMENDED DOSAGES: BREO 100/25 OR 200/25 AGES 18 YEARS AND OLDER; BREO 100/25 AGES 12-17 YEARS, AND BREO 50/25, AGES 5-11 YEARS
0.05MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 12, 2023 RX POWDER INHALATION 11116721 Feb. 26, 2029 MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 5 YEARS AND OLDER. RECOMMENDED DOSAGES: BREO 100/25 OR 200/25 AGES 18 YEARS AND OLDER; BREO 100/25 AGES 12-17 YEARS, AND BREO 50/25, AGES 5-11 YEARS
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION 11116721 Feb. 26, 2029 INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION 11116721 Feb. 26, 2029 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION 11116721 Feb. 26, 2029 MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 5 YEARS AND OLDER. RECOMMENDED DOSAGES: BREO 100/25 OR 200/25 AGES 18 YEARS AND OLDER; BREO 100/25 AGES 12-17 YEARS, AND BREO 50/25, AGES 5-11 YEARS
0.2MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 April 30, 2015 RX POWDER INHALATION 11116721 Feb. 26, 2029 INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
0.2MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 April 30, 2015 RX POWDER INHALATION 11116721 Feb. 26, 2029 MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 5 YEARS AND OLDER. RECOMMENDED DOSAGES: BREO 100/25 OR 200/25 AGES 18 YEARS AND OLDER; BREO 100/25 AGES 12-17 YEARS, AND BREO 50/25, AGES 5-11 YEARS
EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH ANORO ELLIPTA GLAXOSMITHKLINE N203975 Dec. 18, 2013 RX POWDER INHALATION 11090294 Nov. 29, 2030 MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH TRELEGY ELLIPTA GLAXOSMITHKLINE N209482 Sept. 18, 2017 RX POWDER INHALATION 11090294 Nov. 29, 2030 MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) COMPRISING THE ONCE PER DAY ADMINISTRATION OF TRELEGY ELLIPTA, 100 MCG FLUTICASONE FUROATE/62.5 MCG UMECLIDINIUM/25 MCG VILANTEROL

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
0.05MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 12, 2023 RX POWDER INHALATION May 13, 2026 NEW STRENGTH
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION May 13, 2026 NEW PATIENT POPULATION
0.05MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 12, 2023 RX POWDER INHALATION Nov. 13, 2026 PEDIATRIC EXCLUSIVITY
0.1MG/INH;EQ 0.025MG BASE/INH BREO ELLIPTA GLAXO GRP LTD N204275 May 10, 2013 RX POWDER INHALATION Nov. 13, 2026 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Beta-2 adrenergic receptor GPCR AGONIST EC50 9.40 WOMBAT-PK CHEMBL
Beta-3 adrenergic receptor GPCR EC50 6.10 WOMBAT-PK
Beta-1 adrenergic receptor GPCR EC50 6.40 WOMBAT-PK

External reference:

IDSource
D09696 KEGG_DRUG
4032565 VUID
N0000188266 NUI
4032565 VANDF
CHEBI:75037 CHEBI
CHEMBL1198857 ChEMBL_ID
CHEMBL1084172 ChEMBL_ID
C550468 MESH_SUPPLEMENTAL_RECORD_UI
7353 IUPHAR_LIGAND_ID
503070-58-4 SECONDARY_CAS_RN
DB09082 DRUGBANK_ID
028LZY775B UNII
1424883 RXNORM
203032 MMSL
29456 MMSL
29954 MMSL
d08099 MMSL
015022 NDDF
015023 NDDF
702408004 SNOMEDCT_US
702409007 SNOMEDCT_US
720194004 SNOMEDCT_US
C2935023 UMLSCUI
9198 INN_ID
10184665 PUBCHEM_CID
028LZY775B INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Breo Ellipta HUMAN PRESCRIPTION DRUG LABEL 2 0173-0859 POWDER 25 ug RESPIRATORY (INHALATION) NDA 26 sections
Anoro Ellipta HUMAN PRESCRIPTION DRUG LABEL 2 0173-0869 POWDER 25 ug RESPIRATORY (INHALATION) NDA 27 sections
Anoro Ellipta HUMAN PRESCRIPTION DRUG LABEL 2 0173-0869 POWDER 25 ug RESPIRATORY (INHALATION) NDA 27 sections
Breo Ellipta HUMAN PRESCRIPTION DRUG LABEL 2 0173-0882 POWDER 25 ug RESPIRATORY (INHALATION) NDA 26 sections
Trelegy Ellipta HUMAN PRESCRIPTION DRUG LABEL 3 0173-0887 POWDER 25 ug RESPIRATORY (INHALATION) NDA 26 sections
Trelegy Ellipta HUMAN PRESCRIPTION DRUG LABEL 3 0173-0893 POWDER 25 ug RESPIRATORY (INHALATION) NDA 26 sections
Breo Ellipta HUMAN PRESCRIPTION DRUG LABEL 2 0173-0916 POWDER 25 ug RESPIRATORY (INHALATION) NDA 26 sections
Umeclidinium and Vilanterol Ellipta HUMAN PRESCRIPTION DRUG LABEL 2 66993-134 POWDER 25 ug RESPIRATORY (INHALATION) NDA authorized generic 29 sections
Umeclidinium and Vilanterol Ellipta HUMAN PRESCRIPTION DRUG LABEL 2 66993-134 POWDER 25 ug RESPIRATORY (INHALATION) NDA authorized generic 29 sections
Fluticasone Furoate and Vilanterol HUMAN PRESCRIPTION DRUG LABEL 2 66993-135 POWDER 25 ug RESPIRATORY (INHALATION) NDA authorized generic 26 sections
Fluticasone Furoate and Vilanterol HUMAN PRESCRIPTION DRUG LABEL 2 66993-136 POWDER 25 ug RESPIRATORY (INHALATION) NDA authorized generic 26 sections